CINECA IRIS Institutional Research Information System

TABBO', FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.977
EU - Europa 1.343
AS - Asia 748
AF - Africa 17
OC - Oceania 15
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4.107
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.950
CN - Cina 382
IT - Italia 381
SE - Svezia 231
IE - Irlanda 180
DE - Germania 145
SG - Singapore 118
FR - Francia 73
GB - Regno Unito 63
VN - Vietnam 61
AT - Austria 49
JP - Giappone 48
PL - Polonia 39
UA - Ucraina 34
HK - Hong Kong 30
IN - India 29
KR - Corea 28
ES - Italia 27
FI - Finlandia 27
CA - Canada 20
BE - Belgio 18
SA - Arabia Saudita 16
RU - Federazione Russa 15
NL - Olanda 13
AU - Australia 11
CH - Svizzera 11
SN - Senegal 11
TW - Taiwan 11
TR - Turchia 8
MX - Messico 7
RO - Romania 7
GR - Grecia 6
RS - Serbia 6
BY - Bielorussia 4
NZ - Nuova Zelanda 4
CZ - Repubblica Ceca 3
HU - Ungheria 3
MY - Malesia 3
NO - Norvegia 3
UZ - Uzbekistan 3
BR - Brasile 2
CL - Cile 2
IR - Iran 2
MA - Marocco 2
NG - Nigeria 2
PH - Filippine 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
EU - Europa 1
ID - Indonesia 1
IL - Israele 1
KW - Kuwait 1
MM - Myanmar 1
PK - Pakistan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 4.107
Salva come PNG Salva come JPEG
Città #
Chandler 316
Dublin 179
Fairfield 163
Beijing 121
Ashburn 105
Torino 95
Singapore 87
Nyköping 76
Ann Arbor 73
Houston 70
Woodbridge 64
Seattle 60
Wilmington 59
Redwood City 52
Turin 49
Dearborn 48
Cambridge 46
Medford 45
Princeton 44
Vienna 42
Hangzhou 41
Dong Ket 36
Shanghai 33
Pisa 26
Villeurbanne 25
New York 23
Jacksonville 18
Boston 17
Warsaw 17
Boardman 14
Nanjing 13
Seoul 13
Tokyo 13
Fremont 12
Hebei 12
Rome 12
Brussels 11
Chengdu 11
Guangzhou 11
San Diego 10
Las Vegas 9
London 9
Santa Clara 9
Hong Kong 8
Norwalk 8
Central District 7
Changchun 7
Florence 7
Hefei 7
Milan 7
Shenyang 7
Taipei 7
Fuzhou 6
Helsinki 6
Kunming 6
Paris 6
Philadelphia 6
Redmond 6
Thening 6
Zhengzhou 6
Barcelona 5
Changsha 5
Los Angeles 5
Madrid 5
Piemonte 5
Rochester 5
Saint Petersburg 5
San Mateo 5
Xi'an 5
Catania 4
Chicago 4
Falls Church 4
Hyderabad 4
Jinan 4
Lanzhou 4
Mountain View 4
Naples 4
Portland 4
San Antonio 4
San Francisco 4
Somerville 4
Toronto 4
Upper Marlboro 4
Wroclaw 4
Ahmedabad 3
Amsterdam 3
Athens 3
Belgrade 3
Birmingham 3
Boerne 3
Busto Arsizio 3
Central 3
Edinburgh 3
Edmond 3
Frankfurt am Main 3
Guiyang 3
Hamburg 3
Harbin 3
Ivrea 3
Langreo 3
Totale 2.455
Salva come PNG Salva come JPEG
Nome #
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. 347
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario 333
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 245
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 245
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. 174
The influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) Biobank 160
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 149
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 132
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. 125
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 106
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer 103
Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread? 102
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients 96
Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer 92
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 91
Osimertinib-induced Cardiac Dysfunction in EGFRMutated Lung Cancer: A Case Series of Five Patients 86
Corrigendum to “Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario” (Critical Reviews in Oncology / Hematology (2018) 122 (150–156), (S1040842817304857), (10.1016/j.critrevonc.2017.12.015)) 85
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 81
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 81
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 80
Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma 79
Changing paradigms of non-small cell lung cancer treatment 75
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave 72
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 72
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 72
Future perspectives from lung cancer pre-clinical models: new treatments are coming? 70
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 64
Epigenomic evolution in diffuse large B-cell lymphomas 62
Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas 59
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. 59
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: Are we actually ready? 57
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics 57
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC) 54
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives 48
Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center 48
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 46
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 40
Kinomic profiling of tumour xenografts derived from patients with non–small cell lung cancer confirms their fidelity and reveals potentially actionable pathways 40
Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas 38
Resistance to anaplastic lymphoma kinase inhibitors: Knowing the enemy is half the battle won 34
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences 28
Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management 28
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine 27
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All? 27
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center 26
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences 21
RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion 7
Totale 4.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.901
article - articoli 0
book - libri 0
conference - conferenze 252
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.153
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020484 0 0 15 32 31 58 70 64 60 77 40 37
2020/2021678 35 48 46 65 58 46 26 58 56 65 52 123
2021/2022865 71 42 56 60 55 39 59 64 21 105 173 120
2022/20231.040 107 96 41 91 88 223 60 85 115 34 65 35
2023/2024568 68 97 34 37 25 63 40 35 10 50 65 44
2024/2025133 30 103 0 0 0 0 0 0 0 0 0 0
Totale 4.223